| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1998PNAS...9515542I |
| P356 | DOI | 10.1073/PNAS.95.26.15542 |
| P932 | PMC publication ID | 28079 |
| P698 | PubMed publication ID | 9861005 |
| P5875 | ResearchGate publication ID | 235612628 |
| P2093 | author name string | Marquis DM | |
| Victoria EJ | |||
| Iverson GM | |||
| P2860 | cites work | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 |
| Rapid and efficient site-specific mutagenesis without phenotypic selection | Q27860628 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Anticardiolipin antibodies: isotype distribution and phospholipid specificity | Q33456927 | ||
| Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus | Q33458388 | ||
| Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody | Q33503393 | ||
| Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity | Q36157442 | ||
| Complete amino acid sequence of human plasma beta 2-glycoprotein I. | Q36262293 | ||
| Structure of transglutaminases. | Q37594672 | ||
| Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. | Q41206055 | ||
| Immunological specificity and mechanism of action of IgG lupus anticoagulants | Q41384058 | ||
| Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I | Q41674799 | ||
| Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface | Q42084495 | ||
| The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. | Q44828689 | ||
| Some 'antiphospholipid antibodies' bind to beta 2-glycoprotein I in the absence of phospholipid | Q67991471 | ||
| Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 | ||
| Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen | Q68042865 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? | Q68172182 | ||
| Antiphospholipid antibodies | Q68495887 | ||
| Anticardiolipin response in acute infections | Q69588484 | ||
| Structure-function relationships of the complement components | Q69663087 | ||
| Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome | Q71965474 | ||
| Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies | Q71965477 | ||
| Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? | Q72345769 | ||
| "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding | Q72393079 | ||
| [Antiphospholipid and anti beta 2-glycoprotein I antibodies] | Q72547806 | ||
| Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis | Q72585164 | ||
| Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies | Q72776795 | ||
| Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding | Q74477243 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoantibody | Q785022 |
| P304 | page(s) | 15542-15546 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. | |
| P478 | volume | 95 |
| Q35250419 | "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome |
| Q25255895 | A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli |
| Q33915467 | Accelerated atheroma and anti-beta2-glycoprotein I antibodies |
| Q34069117 | Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. |
| Q34790028 | Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis |
| Q35215762 | Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome |
| Q44620496 | Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains |
| Q38108396 | Anti-β2-glycoprotein I antibodies |
| Q38013590 | Antibodies against domain I of β2-glycoprotein I: the one and only? |
| Q40858020 | Antibodies to age-β2 glycoprotein I in patients with anti-phospholipid antibody syndrome. |
| Q37744837 | Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. |
| Q30497721 | Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. |
| Q35680777 | Antiphospholipid syndrome infectious origin |
| Q38596401 | Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review |
| Q36844544 | Antiphospholipid syndrome: laboratory testing and diagnostic strategies |
| Q34467454 | Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I |
| Q39716593 | Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome |
| Q36225236 | Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43 |
| Q73264883 | Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot |
| Q42096240 | Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9 |
| Q33844273 | Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. |
| Q46483595 | Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome |
| Q35181703 | Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease |
| Q74263564 | Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin |
| Q35843950 | Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS |
| Q44618214 | Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q37721607 | Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome |
| Q28291393 | Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318 |
| Q39044818 | Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function |
| Q36774243 | Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome |
| Q80966546 | Genetics of antiphospholipid syndrome |
| Q43801367 | Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome |
| Q58895662 | Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope |
| Q38826804 | Immunotherapeutic strategies in antiphospholipid syndrome |
| Q79157095 | In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome |
| Q57983447 | Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes |
| Q42742480 | Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies |
| Q35824487 | LJP 1082: a toleragen for Hughes syndrome |
| Q36037794 | Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome |
| Q83286175 | Mechanisms of anti-phospholipid antibody formation and action |
| Q37088895 | Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism |
| Q37903952 | Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. |
| Q34227074 | Monoclonal antibodies and other biologic therapies |
| Q64092528 | New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats |
| Q38175886 | New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies |
| Q34140319 | New therapeutic targets for the antiphospholipid syndrome |
| Q28267421 | Pathophysiology of the antiphospholipid syndrome |
| Q38013582 | Pathophysiology of thrombotic APS: where do we stand? |
| Q46373484 | Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity |
| Q33698159 | Pharmacokinetics of LJP 993, a tetrameric conjugate of domain 1 of beta2-glycoprotein I for antiphospholipid syndrome |
| Q55073623 | Platelets activated by the anti-β2GPI/β2GPI complex release microRNAs to inhibit migration and tube formation of human umbilical vein endothelial cells. |
| Q33948737 | Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. |
| Q40551503 | Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome |
| Q30676844 | Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides |
| Q35214636 | Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis |
| Q35535795 | Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. |
| Q37577693 | Recent advances in understanding antiphospholipid syndrome. |
| Q37991066 | Recent developments in our understanding of the antiphospholipid syndrome |
| Q34474881 | Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1 |
| Q88581290 | Renal involvement in antiphospholipid syndrome |
| Q53203652 | Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? |
| Q52036049 | Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. |
| Q36928593 | The antiphospholipid syndrome: still an enigma |
| Q26765406 | The role of anti-phospholipid antibodies in autoimmune reproductive failure |
| Q93020058 | The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS |
| Q55260402 | Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. |
| Q48243949 | β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome |
Search more.